[go: up one dir, main page]

ATE355837T1 - Antitumor-zusammensetzungen enthaltend taxan- derivate - Google Patents

Antitumor-zusammensetzungen enthaltend taxan- derivate

Info

Publication number
ATE355837T1
ATE355837T1 AT02713093T AT02713093T ATE355837T1 AT E355837 T1 ATE355837 T1 AT E355837T1 AT 02713093 T AT02713093 T AT 02713093T AT 02713093 T AT02713093 T AT 02713093T AT E355837 T1 ATE355837 T1 AT E355837T1
Authority
AT
Austria
Prior art keywords
compositions containing
taxane derivatives
containing taxane
antitumor compositions
antitumor
Prior art date
Application number
AT02713093T
Other languages
English (en)
Inventor
Marie-Christine Bissery
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE355837T1 publication Critical patent/ATE355837T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AT02713093T 2001-03-21 2002-03-21 Antitumor-zusammensetzungen enthaltend taxan- derivate ATE355837T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/813,018 US6441026B1 (en) 1993-11-08 2001-03-21 Antitumor compositions containing taxane derivatives

Publications (1)

Publication Number Publication Date
ATE355837T1 true ATE355837T1 (de) 2007-03-15

Family

ID=25211230

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02713093T ATE355837T1 (de) 2001-03-21 2002-03-21 Antitumor-zusammensetzungen enthaltend taxan- derivate

Country Status (19)

Country Link
US (1) US6441026B1 (de)
EP (1) EP1478355B1 (de)
JP (1) JP4467885B2 (de)
CN (2) CN1536995A (de)
AT (1) ATE355837T1 (de)
AU (1) AU2002244877B2 (de)
BR (1) BR0208274A (de)
CA (1) CA2440160C (de)
CY (1) CY1106582T1 (de)
DE (1) DE60218751T2 (de)
DK (1) DK1478355T3 (de)
EA (1) EA006878B1 (de)
ES (1) ES2282400T3 (de)
HU (1) HUP0500478A2 (de)
IL (1) IL157992A (de)
MX (1) MXPA03008539A (de)
PT (1) PT1478355E (de)
SI (1) SI1478355T1 (de)
WO (2) WO2002074232A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
EE05417B1 (et) * 2001-03-14 2011-06-15 Bristol-Myers Squibb Company Epotilooni analoogide ja kemoterapeutikumide kombinatsiooni kasutamine teraapias
ITRM20020191A1 (it) * 2002-04-08 2003-10-08 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att
MEP16308A (en) * 2002-05-17 2010-06-10 Aventis Pharma Sa Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
WO2004035034A2 (en) * 2002-10-16 2004-04-29 Ilex Products, Inc. Clofarabine and taxane chemotherapy combination
ITMI20030317A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale.
WO2004103344A1 (en) * 2003-05-20 2004-12-02 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising a liposomal platinum complex
CN100340296C (zh) * 2005-02-03 2007-10-03 山东蓝金生物工程有限公司 一种抗癌体内植入剂
CN103169729A (zh) * 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
WO2007067417A1 (en) * 2005-12-05 2007-06-14 Nitto Denko Corporation Polyglutamate-amino acid conjugates and methods
EP1913958B1 (de) * 2006-08-03 2009-12-23 Sanofi-Aventis Antitumorale Zusammensetzungen enthaltend Acetylcyclopropyl Docetaxel und Trastuzumab
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
EP2144631A2 (de) * 2007-04-10 2010-01-20 Nitto Denko Corporation Multifunktionale polyglutamat-wirkstoffträger
DK2155254T3 (da) * 2007-05-09 2013-03-04 Nitto Denko Corp Med platinlægemidler konjugerede polymere
EP2155253A2 (de) * 2007-05-09 2010-02-24 Nitto Denko Corporation Polyglutamatkonjugate und polyglutamat-aminosäure-konjugate mit mehreren wirkstoffen
EP2155255B1 (de) * 2007-05-09 2013-08-14 Nitto Denko Corporation Zusammensetzungen, die eine hydrophobe Verbindung und ein Polyaminosäurekonjugat beinhalten
CN104096236A (zh) * 2008-03-06 2014-10-15 日东电工株式会社 用于治疗癌症的聚合物紫杉醇结合物和方法
MX369728B (es) 2010-03-29 2019-11-20 Abraxis Bioscience Llc Métodos para mejorar suministro de fármacos y efectividad de agentes terapéuticos.
EP3141245A1 (de) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Verfahren zur behandlung von karzinomen
KR20190130050A (ko) 2010-06-04 2019-11-20 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
AU2011325989C1 (en) * 2010-11-12 2015-04-23 Endocyte, Inc. Methods of treating cancer
CN102241648B (zh) * 2011-01-31 2016-08-03 沈阳东星医药科技有限公司 抗多药耐药紫杉烷类衍生物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4876399A (en) 1987-11-02 1989-10-24 Research Corporation Technologies, Inc. Taxols, their preparation and intermediates thereof
US5136060A (en) 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
US5015744A (en) 1989-11-14 1991-05-14 Florida State University Method for preparation of taxol using an oxazinone
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
AU2005692A (en) 1991-05-08 1992-12-21 United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancer
US5645988A (en) 1991-05-08 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying drugs with selective effects against cancer cells
US5284864A (en) 1991-09-23 1994-02-08 Florida State University Butenyl substituted taxanes and pharmaceutical compositions containing them
US5229526A (en) 1991-09-23 1993-07-20 Florida State University Metal alkoxides
US5262409A (en) 1991-10-11 1993-11-16 Fred Hutchinson Cancer Research Center Binary tumor therapy
US5294737A (en) 1992-02-27 1994-03-15 The Research Foundation State University Of New York Process for the production of chiral hydroxy-β-lactams and hydroxyamino acids derived therefrom
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
EP0982028A1 (de) * 1998-08-20 2000-03-01 Aventis Pharma S.A. Neue Verwendung von Taxoidverbindungen

Also Published As

Publication number Publication date
AU2002244877B2 (en) 2006-07-20
US20020031505A1 (en) 2002-03-14
IL157992A (en) 2008-08-07
CN1536995A (zh) 2004-10-13
JP4467885B2 (ja) 2010-05-26
DE60218751D1 (de) 2007-04-19
HUP0500478A2 (hu) 2005-08-29
EA006878B1 (ru) 2006-04-28
MXPA03008539A (es) 2004-08-11
CN101590057A (zh) 2009-12-02
ES2282400T3 (es) 2007-10-16
EP1478355A2 (de) 2004-11-24
SI1478355T1 (sl) 2007-08-31
EA200301047A1 (ru) 2004-06-24
US6441026B1 (en) 2002-08-27
JP2004536790A (ja) 2004-12-09
DK1478355T3 (da) 2007-07-02
WO2002074289A2 (en) 2002-09-26
WO2002074232A2 (en) 2002-09-26
WO2002074289A3 (en) 2004-09-02
DE60218751T2 (de) 2007-11-22
EP1478355B1 (de) 2007-03-07
BR0208274A (pt) 2004-07-13
CY1106582T1 (el) 2012-01-25
CA2440160C (en) 2011-07-05
CA2440160A1 (en) 2002-09-26
PT1478355E (pt) 2007-05-31

Similar Documents

Publication Publication Date Title
ATE355837T1 (de) Antitumor-zusammensetzungen enthaltend taxan- derivate
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
BRPI0515012A (pt) substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
YU49101A (sh) Karboksiaril supstituisani difenil karbamidi kao inhibitori raf kinaze
NO943002D0 (no) Fosfono-oksymetyletere av taxanderivater
BR0012046A (pt) Composto heterocìclico, composição farmacêutica, inibidor de ativação de ap-1 ou um inibidor da ativação de nf-kappab, inibidor da produção de citocina inflamatória, e, inibidor da produção de metaloprotease de matriz ou inibidor da expressão do fator de adesão de célula inflamatória
TW200505890A (en) Breast cancer-resistant protein inhibitor
BR0208741A (pt) Derivados de piperidina
ATE359806T1 (de) Nachweis und therapie von empfindlichem plaque mit photodynamischen verbindungen
BRPI0213063B8 (pt) composto antibiótico de ação dupla, sua composição farmacêutica e seu uso
BR9909994A (pt) Quinolinas usadas como inibidores de mrs e bactericidas
CY1110449T1 (el) Συνδυασμος δοκεταξελης και φλαβοπιριδinολης
DK0991424T3 (da) Farmaceutiske præparater omfattende en inhibitor for aldosereduktase og en inhibitor for ACE
CA2218663A1 (en) Benzisoxazole and indazole derivatives as antipsychotic agents
ATE268175T1 (de) Decursin-enthaltende pharmazeutische zusammensetzungen
NO994408D0 (no) Dolastatin-15 derivater i kombinasjon med taxaner
DE60118914D1 (de) Pharmazeutische zusammensetzungen die acryloyl-substituierte distamycin-derivate und topoisomerase i und ii inhibitoren enthalten
NO20060509L (no) Halvfaste systemer inneholdende azetidinderivater
ATE401325T1 (de) C10-carbamoyloxysubstituierte taxane als antitumormittel
AU2002214197A1 (en) Macrolides
ATE432928T1 (de) C10-taxanester als antitumormittel
DE60133600D1 (de) C7-carbamoyloxysubstituierte taxane als antitumormittel
EE200200688A (et) Akrüloüüldistamütsiini derivaati, mikrotuubulivastast toimeainet ja/või antimetaboliiti sisaldav farmatseutiline kompositsioon, derivaadi kasutamine tuumorivastase ravimi valmistamiseks ning kombineeritud ravimpreparaat
WO2008015578A3 (en) Antitumor compositions containing acetylcyclopropyl docetaxel and trastuzumab
BR0312734A (pt) Composto de indolina e uso medicinal do mesmo

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1478355

Country of ref document: EP